Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

N4 Pharma Plc (N4P)

Price 0.65p on 22-11-2024 at 17:30:01
Change 0.00p 0%
Buy 0.70p
Sell 0.60p
Buy / Sell N4P Shares
Last Trade: Buy 214.00 at 0.70p
Day's Volume: 5,779
Last Close: 0.65p
Open: 0.65p
ISIN: GB00BYW8QM32
Day's Range 0.65p - 0.65p
52wk Range: 0.412p - 1.30p
Market Capitalisation: £3m
VWAP: 0.642447p
Shares in Issue: 395m

Recent Trades History N4 Pharma Plc (N4P)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 214 0.70p Ordinary
16:05:17 - 22-Nov-24
Buy* 285 0.70p Ordinary
14:10:25 - 22-Nov-24
Sell* 160 0.60p SI Trade
14:07:02 - 22-Nov-24
Buy* 214 0.70p Ordinary
11:43:54 - 22-Nov-24
Sell* 166 0.60p SI Trade
11:42:39 - 22-Nov-24
Buy* 285 0.70p Ordinary
08:02:50 - 22-Nov-24
Sell* 3,000 0.60p SI Trade
08:00:03 - 22-Nov-24
Buy* 1,455 0.70p SI Trade
08:00:03 - 22-Nov-24

Share Price History for N4 Pharma Plc

Time period:
to
Date Open High Low Close Volume

Share News for N4 Pharma Plc

EARNINGS: Metals One advances Black Schist, N4 generates revenue

24th Sep 2024 15:01

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: N4 Pharma celebrates chemistry work update on Nuvec

20th Aug 2024 11:52

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology Nuvec - Notes SRI International has successfully completed the chemistry work and shown that a fox three molecular guidance system can be added to Nuvec without altering its loading capability. Chief Executive Nigel Theobald says: "This is an exciting development for us as it clearly shows that Nuvec is capable of targeting specific cells via the addition of a relevant ligand, something the industry is actively looking for. We will now start working on a combined marketing pitch deck allowing SRI and N4 Pharma to present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs." N4 Pharma says the next step is to show that small interfering RNA still retains its functionality in the target cell. Read More

AIM WINNERS & LOSERS: Shuka Minerals down on CLN drawdown

20th Aug 2024 10:24

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

TRADING UPDATES: Topps Tiles sales dip; Physiomics completes placing

3rd Jul 2024 12:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

N4 Pharma raises GBP630,000 to advance primary work streams

7th Jun 2024 12:32

(Alliance News) - N4 Pharma PLC on Friday said it has raised GBP630,000 through a placing and subscription of shares. Read More

FTSE 100 Latest
Value8,262.08
Change112.81

Login to your account

Forgot Password?

Not Registered